GlobeNewsWire
07 Jan 2026, 21:05 UTC · 43w ago
iMDx Announces “JPM Week” and “BTIG Snowbird” Conference Participation
Impact · against what's priced in
iMDx shares may see modest upside following reports of timely FDA substantive review and favorable Medicare reimbursement policies for GraftAssureDx. While conference participation is routine, the progress toward marketing authorization provides a concrete catalyst for potential revenue growth.
- IMDX+0.40
No priced-in read yet
- In context
The company reports that the FDA has completed the current portion of the substantive review for GraftAssureDx in a timely manner and notes a favorable Medicare reimbursement policy, both of which are critical precursors to commercialization.
Read from the article alone
Search tags
